DEPLOYDatabase

Company

Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare and pharmaceutical company with a surgical robotics division that develops the MONARCH platform for…

Founded
1886
HQ
New Brunswick, New Jersey, USA
Status
public (NYSE: JNJ)

The verified answer

As of Aug 2026, DEPLOY verifies Johnson & Johnson: 1 model, 1 deployment across 1 region, 5 active incidents. 3 sources back the record.

CategorySurgical robots

Overview

Johnson & Johnson (NYSE: JNJ) is a global healthcare and pharmaceutical company with a surgical robotics division that develops the MONARCH platform for bronchoscopic procedures and the OTTAVA surgical robotics system. The company's robotics portfolio spans robotic-assisted surgery, digital surgery, and minimally invasive interventions.

Verified record

Verified deployments
1 deployment on file
Active incidents
5 incidents on file

Key facts

Product

MONATCH bronchoscopic robot, OTTAVA surgical robotics

Status

Pre-market: FDA De Novo submitted Jan 7 2026; NOT cleared; zero installed base.

Stock listing

Developing division

MedTech/Ethicon

Company type

Global healthcare company

Revenue

\8B (2025, NYSE: JNJ)

Data & sources

Press releases

1

News coverage

1

Web sources

1

3 sources backing this record.View all →

Explainers

Plain-language answers to the questions people ask about Johnson & Johnson, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →
What is Johnson & Johnson Ottava?
Johnson & Johnson Ottava is a surgical robotics platform under development by J&J. Per Agent A foundational ingest, Ottava submitted a De Novo to FDA in January 2026; FDA records list Ottava as 'not authorized to be marketed.' Per DEPLOY's FDA-clearance-as-gating-event framework, Ottava sits at research tier despite J&J's corporate scale. Maturity: research. The pre-market positioning despite J&J's massive medical-device portfolio is the editorial throughline: DEPLOY's framework treats Ottava at the same research tier as Vicarious Surgical V1's distressed pre-market state because both lack the verified gating event. Surfacing this transparently demonstrates the framework discipline applied to household-name corporate scale.Read the full explainer →

Current leadership (1)

Safety record

5 incidents on record (2 moderate, 2 minor). Most recent: Jul 2026.

moderate
2
minor
2
Severity not classified
1

Most recent: Jul 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Johnson & Johnson (5)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operator customers (1)

Recent coverage

Johnson & Johnson in third-party press

Peer companies